Focal Segmental Glomerulosclerosis
A rare glomerular kidney-scarring disease, Focal Segmental Glomerulosclerosis (FSGS) is a disease with prevalent cases of 196,333 in the 7MM as estimated by DelveInsight in 2017. However, poor knowledge of the disease remains a major concern.
At present, there is a dire need for heightened R&D in the field for a better understanding of the physio-pathology of FSGS for better diagnostic tests and treatments.
Know more about the condition, its causes, symptoms, epidemiological insights and available therapeutic options through DelveInsight’s newsletter.
The newsletter covers the recent happenings in Focal Segmental Glomerulosclerosis Market, its pipeline therapies, key companies working in the domain, significant collaborations, licensing opportunities, and conferences that are taking place in the field.
For rich, precise and accurate FSGS Market insights, fill up a simple form towards the right and get the newsletter delivered into your inbox.
Join DelveInsight’s mailer list and get all the updates and recent happenings in the Life Science vertical delivered right in your inbox.
Know more about What's covered:
- Indication overview
- Signs, symptoms, and diagnosis
- Treatment approaches
- Key Companies
- Pipeline drugs
- R&D in the field
- Recent happenings
- Top conferences
- Support from International organizations
